Evidence map›Paper›PMID 36951156›Full record

Trial reportHaematologica2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.

Andrew H Wei, Gail J Roboz, Herve Dombret, Hartmut Dohner, Andre C Schuh, Pau Montesinos, Dominik Selleslag, Sergey N Bondarenko, Thomas Prebet, Yinzhi Lai and 3 more

Abstract readClinical Trial, Phase IIILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Epigenetic Targeting in Myeloid Malignancies.Advances in experimental medicine and biology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrew H WeiDepartment of Clinical Haematology, The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne. andrew.wei@petermac.org.
Gail J RobozWeill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, New York, NY.
Herve DombretHematology, Hopital Saint-Louis, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France; Institut de Recherche Saint-Louis, Universite Paris Cite, Paris.
Hartmut DohnerDepartment of Internal Medicine III, Ulm University Hospital, Ulm.
Andre C SchuhPrincess Margaret Cancer Centre, Toronto, ON.
Pau MontesinosHospital Universitario y Politecnico La Fe, Valencia.
Dominik SelleslagAZ Sint-Jan Brugge-Oostende AV, Bruges.
Sergey N BondarenkoRM Gorbacheva Research Institute, Pavlov University, St. Petersburg.
Thomas PrebetBristol Myers Squibb, Summit, NJ.
Yinzhi LaiBristol Myers Squibb, Summit, NJ.
Barry SkikneBristol Myers Squibb, Summit, NJ, USA; University of Kansas Cancer Center, Kansas City, KS.
C L BeachBristol Myers Squibb, Summit, NJ.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AzacitidineLeukemia, Myeloid, AcuteAntimetabolites, AntineoplasticHumansRemission InductionAntimetabolites, AntineoplasticAzacitidine

Identifiers

PMID36951156
PMCPMC10542842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.